BackPDS Biotechnology Overview

PDS Biotechnology Other Current Assets

PDS Biotechnology's other current assets is $1.4B.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.45B

Peer average / median

Loading

PDS Biotechnology Other Current Assets History

Loading

PDS Biotechnology vs. peers: Other Current Assets Comparison

Loading

PDS Biotechnology Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PDS Biotechnology (PDSB) FAQ

PDS Biotechnology (PDSB) currently reports a other current assets of $1.4B as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore PDS Biotechnology's other current assets history and peer comparisons.

PDS Biotechnology's other current assets changed from $0 to $1.4B (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PDS Biotechnology reported $1.4B in other current assets as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $1.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PDS Biotechnology, and consider following PDSB for alerts when major investors trade the stock.

PDS Biotechnology is classified in the Healthcare sector. On other current assets, it currently shows $1.4B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PDSB with unrelated industries.